Navigation Links
Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
Date:10/22/2013

SEOUL, South Korea, Oct. 22, 2013 /PRNewswire/ -- Samsung BioLogics today announced that Samsung BioLogics and F. Hoffmann-La Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction. Terms of the agreement will not be disclosed, including financial terms and products to be manufactured.

(Photo: http://photos.prnewswire.com/prnh/20131022/HK01710 )
(Photo: http://www.prnasia.com/sa/2013/10/22/2013102214483444486.html )

"We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards," said Tae-Han Kim, president and CEO of Samsung BioLogics. "This collaboration with the world's largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing."

About Samsung BioLogics

Samsung BioLogics is a full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry. Our facilities are custom designed for monoclonal antibody & recombinant protein production with maximum flexibility. Our one-stop services include cell line generation, process and analytical method development, analytical services, clinical and commercial bulk cGMP manufacturing of drug substance and drug product meeting the highest standards of quality and global regulatory compliance. For additional information about the company, please visit http://www.samsungbiologics.com.

Samsung Disclaimer

This press release may contain certain forward-looking statements that reflect our current views and expectations with respect to our performance, businesses, and future events. Please understand that these statements are subject to a number of risks, uncertainties, and assumptions, any of which could cause actual results to materially differ from the plans, objectives, expectations, estimates, and intentions we express. In no event will we or any of our subsidiaries, affiliates, directors, officers, agents, or employees be liable before any third party, including investors, for any investment or business decision made or action taken based on information and statements contained in this press release or for any consequential, special, or similar damages.

Contact:
Samsung BioLogics
Media:
Changsik Park
82-32-455-3710
changsiik.park@samsung.com


'/>"/>
SOURCE Samsung BioLogics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Samsung Thales signs Development Agreement with Novelda
2. iLuv Now Shipping Protective and Stylish Accessories for the Just-Announced Samsung GALAXY Note 8.0
3. iLuv Announces a New Lineup of Cases and Accessories for the New Samsung GALAXY Tab 3
4. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
5. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
6. Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Adeona Becomes Synthetic Biologics, Inc.
9. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
10. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
11. CMC Biologics Highlights Technical Acumen at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Morf Media ... compliance training platform on mobile devices, today released a new interactive Food ... Medical Devices. The course is essential for owners or operators of places of ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... facilitates accessibility to unique bioresearch materials from laboratories across the globe, today announced ... scramble to increase the pace of research toward treatment and prevention measures for ...
(Date:5/3/2016)... ... May 03, 2016 , ... According to world renowned ... definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or radiation. ... be made. , New technology has enabled doctors to administer higher doses of ...
(Date:5/2/2016)... ... 02, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher ... Remote Desktop modules to its flagship X-Win32 PC X server. The new modules ... the user’s PC over encrypted SSH. , Traditionally, users of PC X servers deploy ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):